David Benedicto
Plus aucun poste en cours
Fortune : 30 $ au 31/03/2024
Profil
David C.
Benedicto worked as a Controller at HERC Products, Inc. and BAE Systems, Inc. He also worked as an Accounting Manager at Trius Therapeutics, Inc. Currently, he is the Chief Financial & Accounting Officer at DMK Pharmaceuticals Corp.
Mr. Benedicto holds an MBA from the University of Redlands and an undergraduate degree from the University of St. La Salle.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 06/10/2023 | 569 ( 0,01% ) | 30 $ | 31/03/2024 |
Anciens postes connus de David Benedicto
| Sociétés | Poste | Fin |
|---|---|---|
| DMK PHARMACEUTICALS CORPORATION | Director of Finance/CFO | 21/07/2023 |
BAE Systems, Inc.
 BAE Systems, Inc. Information Technology ServicesTechnology Services BAE Systems, Inc. provides support and service solutions for defense, intelligence and civilian systems. The firm offers ship repair, maintenance, modernization, conversion and overhaul services for the U.S. Navy, government, commercial and private customers. It operates full-service shipyards in Alabama, Florida, California, Virginia and Hawaii. The company was founded on November 30, 1999 and is headquartered in Arlington, VA. | Comptroller/Controller/Auditor | - |
| H.E.R.C. PRODUCTS INC. | Comptroller/Controller/Auditor | - |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Comptroller/Controller/Auditor | - |
Formation de David Benedicto
| University of Redlands | Masters Business Admin |
| University of St. La Salle | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| H.E.R.C. PRODUCTS INC. | Process Industries |
| DMK PHARMACEUTICALS CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
BAE Systems, Inc.
BAE Systems, Inc. Information Technology ServicesTechnology Services BAE Systems, Inc. provides support and service solutions for defense, intelligence and civilian systems. The firm offers ship repair, maintenance, modernization, conversion and overhaul services for the U.S. Navy, government, commercial and private customers. It operates full-service shipyards in Alabama, Florida, California, Virginia and Hawaii. The company was founded on November 30, 1999 and is headquartered in Arlington, VA. | Technology Services |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
